Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure
V Cernaro, E Longhitano, V Calabrese… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Among the clinical and metabolic complications of progressive chronic kidney
disease (CKD), CKD-mineral bone disorder (CKD-MBD) significantly contributes to morbidity …
disease (CKD), CKD-mineral bone disorder (CKD-MBD) significantly contributes to morbidity …
An innovative lanthanum carbonate grafted microfibrous composite for phosphate adsorption in wastewater
Excessive presence of phosphorus in waters can cause eutrophication, a global unsolved
environmental problem that has caused harmful effects to our eco-system and the source of …
environmental problem that has caused harmful effects to our eco-system and the source of …
Use of proton pump inhibitors in dialysis patients: a double-edged sword?
G Desbuissons, L Mercadal - Journal of Nephrology, 2021 - Springer
Large cohort-based studies have shown that proton pump inhibitors (PPIs) are linked to rare
but multiple and varied secondary events when used in the general population. Although …
but multiple and varied secondary events when used in the general population. Although …
Proton pump inhibitors, histamine-2 receptor antagonists, and hip fracture risk among patients on hemodialysis
C Vangala, J Niu, CR Lenihan, WE Mitch… - Clinical Journal of the …, 2018 - journals.lww.com
Results We studied 4551 cases and 45,510 controls. Patients were older, more likely to be
female and white, and had shorter dialysis vintage; fewer were obese. A larger proportion of …
female and white, and had shorter dialysis vintage; fewer were obese. A larger proportion of …
Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders. An in vitro study
SP Schumacher, LJ Schurgers, MG Vervloet… - …, 2019 - Wiley Online Library
Aim Hyperphosphataemia is associated with increased mortality and morbidity in end stage
renal disease. Despite phosphate binder therapy, a large proportion of patients do not reach …
renal disease. Despite phosphate binder therapy, a large proportion of patients do not reach …
Control of Endogenous Phosphorus Release at the Sediment–Water Interface by Lanthanum-Modified Fly Ash
Y Pan, G Liu, B Chai, X Lei, L He, S Cheng, Y Wang… - Coatings, 2022 - mdpi.com
This study optimizes the modification and granulation of fly ash to make it more stable at the
sediment–water interface. Through laboratory simulations, the modified fly ash pellets were …
sediment–water interface. Through laboratory simulations, the modified fly ash pellets were …
Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis …
H Minakuchi, T Yoshida, N Kaburagi, T Fujino… - Renal …, 2020 - Taylor & Francis
Because end-stage renal disease patients undergoing hemodialysis frequently take acid
suppressants for the treatment or prevention of gastrointestinal diseases, it is important to …
suppressants for the treatment or prevention of gastrointestinal diseases, it is important to …
[图书][B] ACSM's Nutrition for Exercise Science
D Benardot - 2024 - books.google.com
An invaluable resource for both exercise science majors and non-majors, ACSM's Nutrition
for Exercise Science, 2nd Edition, demystifies the relationship between nutrition and …
for Exercise Science, 2nd Edition, demystifies the relationship between nutrition and …
Influence of proton pump inhibitors and histamine H2 receptor antagonists on serum phosphorus level control by calcium carbonate in patients undergoing …
M Tatsuzawa, R Ogawa, A Ohkubo… - … Health Care and …, 2016 - Springer
Background Hyperphosphatemia is one of the common complications in patients
undergoing hemodialysis. Although calcium carbonate (CaC) is often used to control serum …
undergoing hemodialysis. Although calcium carbonate (CaC) is often used to control serum …
Proton pump inhibitors in kidney disease
B Lazarus, ME Grams - Clinical Journal of the American Society of …, 2018 - journals.lww.com
Proton pump inhibitors (PPIs) are one of the most frequently used classes of medications in
the world, and they are particularly common among patients receiving hemodialysis. In …
the world, and they are particularly common among patients receiving hemodialysis. In …